カツマタ ヤスヒロ
  勝又 康弘
   所属   医学部 医学科(東京女子医科大学病院)
   職種   講師
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods.
掲載誌名 正式名:Immunological medicine
略  称:Immunol Med
ISSNコード:25785826/25785826
掲載区分国外
巻・号・頁 43(1),pp.47-56
著者・共著者 Katsumata Yasuhiro, Okamoto Yuko, Moriyama Takahito, Moriyama Rina, Kawamoto Manabu, Hanaoka Masanori, Uchida Keiko, Nitta Kosaku, Harigai Masayoshi
発行年月 2020/03
概要 Associations between anti-M-type phospholipase A2 receptor (PLA2R) antibodies and disease activity and prognosis have been suggested in primary membranous nephropathy (MN); however, more evidence is needed. We aimed to establish a clinically useful method to measure anti-PLA2R antibodies. We developed a western blot assay and a cell-based enzyme-linked immunosorbent assay (ELISA). Anti-PLA2R antibodies were evaluated retrospectively using these assays and the commercial solid-phase ELISA. Anti-PLA2R antibodies were detected in 12, 6, and 12 out of 23 Japanese patients with biopsy-proven primary MN using the western blot, the cell-based ELISA, and the solid-phase ELISA, respectively. The samples of the lupus MN patients tested negative. The levels of proteinuria correlated moderately with the titres of anti-PLA2R antibodies measured by the three methods (r = 0.39-0.47). Anti-PLA2R antibodies were significantly associated with physicians' decisions on immunosuppressive treatment without prior knowledge of anti-PLA2R antibody positivity (p < .01). In the longitudinal analysis, the titres of anti-PLA2R antibodies measured by the solid-phase ELISA declined significantly following treatment (p = .03). In conclusion, these results suggest the usefulness of anti-PLA2R antibody as a diagnostic, prognostic, and surrogate biomarker in primary MN. The three methods proved to be reliable for measuring anti-PLA2R antibody titres, but their performances differ.
DOI 10.1080/25785826.2019.1710079
PMID 31910103